These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2876514)

  • 41. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroleptic-resistant schizophrenics.
    Murray JB
    J Psychol; 1989 Jan; 123(1):69-78. PubMed ID: 2564435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of clinical status of schizophrenic patients by the WAIS comprehension subtest.
    Bigelow LB; Donnelly EP; Torrey EF; Lee CA
    J Clin Psychiatry; 1979 Jun; 40(6):258-61. PubMed ID: 36371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased positive thought disorder with illness duration in patients with schizophrenia.
    Maeda K; Kasai K; Uetsuki M; Hata A; Araki T; Rogers MA; Yamasue H; Iwanami A
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):687-90. PubMed ID: 18081634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lateral ventricular size, psychopathology, and medication response in the psychoses.
    Luchins DJ; Lewine RR; Meltzer HY
    Biol Psychiatry; 1984 Jan; 19(1):29-44. PubMed ID: 6142730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suspension of neuroleptic therapy in acute schizophrenia.
    Kuhs H; Eikelmann B
    Pharmacopsychiatry; 1988 Jul; 21(4):197-202. PubMed ID: 2905064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medication, logic, and schizophernic thinking: a reply to Marini.
    Ho DY
    J Genet Psychol; 1976 Sep; 129(1st Half):93-5. PubMed ID: 9471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
    Byerly MJ; Nakonezny PA; Rush AJ
    Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Schizophrenia and violence, incidence and risk factors: a Tunisian sample].
    Ellouze F; Ayedi S; Masmoudi S; Bakri L; Chérif W; Zramdini R; Largueche M; Amri H; Ben Abla T; M'rad MF
    Encephale; 2009 Sep; 35(4):347-52. PubMed ID: 19748371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subclinical thought disorder in first-degree relatives of schizophrenic patients. Results from a matched-pairs study with the Thought Disorder Index.
    Hain C; Maier W; Hoechst-Janneck S; Franke P
    Acta Psychiatr Scand; 1995 Oct; 92(4):305-9. PubMed ID: 8848957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bromocriptine in augmentation of antipsychotic response in chronic schizophrenia: a negative pilot report.
    Wells BG; Chu CC; Abi-Darghum A; Saini TS
    Pharmacopsychiatry; 1991 Jul; 24(4):118-20. PubMed ID: 1684441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry.
    Levine J; Martine T; Feraro R; Kimhi R; Bracha HS
    Neuropsychobiology; 1997; 36(1):22-4. PubMed ID: 9211440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of haloperidol on thought disorder and IQ in schizophrenia.
    Gold JM; Hurt SW
    J Pers Assess; 1990; 54(1-2):390-400. PubMed ID: 2179521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
    Taira M; Hashimoto T; Takamatsu T; Maeda K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thought disorder. A function of schizophrenia, mania, or psychosis?
    Marengo J; Harrow M
    J Nerv Ment Dis; 1985 Jan; 173(1):35-41. PubMed ID: 3965610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
    Rapaport MH; Wolkowitz O; Kelsoe JR; Pato C; Konicki PE; Pickar D
    Neuropsychopharmacology; 1993 Sep; 9(2):111-5. PubMed ID: 8105790
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained attention and positive formal thought disorder in schizophrenia.
    Pandurangi AK; Sax KW; Pelonero AL; Goldberg SC
    Schizophr Res; 1994 Sep; 13(2):109-16. PubMed ID: 7986767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose zotepine in the maintenance treatment of schizophrenia.
    Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.